Back to News
Mar 13, 2026 12:00 PM

Why Is ImmunityBio Stock Soaring On Friday?

ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform.

• ImmunityBio shares are powering higher. Why is IBRX stock surging?

Establishes Safe, Reproducible, Scalable Manufacturing Pathway

ImmunityBio completed its NK2022 (Cancer and Healthy Volunteers) and NK2023 (Healthy Volunteers) programs, which evaluated the safety and reproducibility of its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy.

Sixty-four subjects participated, with no serious adverse events reported, and the company highlighted its ability to generate up to five billion NK cells from a single apheresis collection.

Additionally, the company is advancing its phase 1 trial (QUILT-3.076), combining M-ceNK cells with ANKTIVA, which has demonstrated promising ...